Search research articles
Contact Us
Filters
Showing results (201-210 of 358) with videos related to
Page
of 36
Sort By:
The Lancet. HIV
|
October 12, 2019
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
Giuseppe Pantaleo, Holly Janes, Shelly Karuna, et al.
The Journal of Infectious Diseases
|
November 19, 2014
HIV Type 1 Disease Progression to AIDS and Death in a Rural Ugandan Cohort Is Primarily Dependent on Viral Load Despite Variable Subtype and T-Cell Immune Activation Levels
Michael A Eller, Marc S Opollo, Michelle Liu, et al.
Journal of Virology
|
June 23, 2021
Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth
Yifan Li, Hongjun Bai, Eric Sanders-Buell, et al.
Plos Pathogens
|
August 4, 2016
Temporal Dynamics of CD8+ T Cell Effector Responses during Primary HIV Infection
Korey R Demers, George Makedonas, Marcus Buggert, et al.
The Journal of Infectious Diseases
|
October 29, 2002
Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells
Mary A Marovich, John R Mascola, Michael A Eller, et al.
Plos One
|
May 19, 2016
Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial
Agricola Joachim, Asli Bauer, Sarah Joseph, et al.
AIDS Research and Human Retroviruses
|
August 12, 2003
A new circulating recombinant form, CRF15_01B, reinforces the linkage between IDU and heterosexual epidemics in Thailand
Sodsai Tovanabutra, Veerachai Watanaveeradej, Kwanjai Viputtikul, et al.
The Journal of Infectious Diseases
|
February 25, 2016
Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene
Robert J O'Connell, Jean-Louis Excler, Victoria R Polonis, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin
|
April 8, 2022
HIV pre-exposure prophylaxis was associated with no impact on sexually transmitted infection prevalence in a high-prevalence population of predominantly men who have sex with men, Germany, 2018 to 2019
Hendrik Streeck, Klaus Jansen, Trevor A Crowell, et al.
Plos One
|
May 22, 2026
HIV incidence among sexually active young males and females in Kisumu County, Western Kenya
John Owuoth, Chiaka Nwoga, Valentine Sing'oei, et al.
Page
of 36
Search research articles
Search
Showing results (201-210 of 358) with videos related to
Sort By:
Page
of 36
The Lancet. HIV
|
October 12, 2019
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
Giuseppe Pantaleo, Holly Janes, Shelly Karuna, et al.
The Journal of Infectious Diseases
|
November 19, 2014
HIV Type 1 Disease Progression to AIDS and Death in a Rural Ugandan Cohort Is Primarily Dependent on Viral Load Despite Variable Subtype and T-Cell Immune Activation Levels
Michael A Eller, Marc S Opollo, Michelle Liu, et al.
Journal of Virology
|
June 23, 2021
Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth
Yifan Li, Hongjun Bai, Eric Sanders-Buell, et al.
Plos Pathogens
|
August 4, 2016
Temporal Dynamics of CD8+ T Cell Effector Responses during Primary HIV Infection
Korey R Demers, George Makedonas, Marcus Buggert, et al.
The Journal of Infectious Diseases
|
October 29, 2002
Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells
Mary A Marovich, John R Mascola, Michael A Eller, et al.
Plos One
|
May 19, 2016
Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial
Agricola Joachim, Asli Bauer, Sarah Joseph, et al.
AIDS Research and Human Retroviruses
|
August 12, 2003
A new circulating recombinant form, CRF15_01B, reinforces the linkage between IDU and heterosexual epidemics in Thailand
Sodsai Tovanabutra, Veerachai Watanaveeradej, Kwanjai Viputtikul, et al.
The Journal of Infectious Diseases
|
February 25, 2016
Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene
Robert J O'Connell, Jean-Louis Excler, Victoria R Polonis, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin
|
April 8, 2022
HIV pre-exposure prophylaxis was associated with no impact on sexually transmitted infection prevalence in a high-prevalence population of predominantly men who have sex with men, Germany, 2018 to 2019
Hendrik Streeck, Klaus Jansen, Trevor A Crowell, et al.
Plos One
|
May 22, 2026
HIV incidence among sexually active young males and females in Kisumu County, Western Kenya
John Owuoth, Chiaka Nwoga, Valentine Sing'oei, et al.
Page
of 36